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Stem cell-based cellular therapy is a promising tool for the treatment of pathological conditions with underlying severe tissue
damage or malfunction like in chronic cardiovascular, musculoskeletal, or inflammatory conditions. One of the biggest technical
challenges of the use of natural stem cells, however, is the prevention of their premature senescence during therapeutical
manipulations. Culturing stem cells under hypoxic conditions is believed to be a possible route to fulfill this goal. Here, we
review current literature data on the effects of hypoxia on bone marrow-derived mesenchymal stromal cells, one of the most
popular tools of practical cellular therapy, in the context of their senescence.
1. Introduction
Cellular therapy is a rapidly evolving field of regenerative
medicine to regenerate damaged or injured tissues [1]. In
order to fulfill the objectives of this therapeutic approach,
the use of stem cells seems to be one of the most appropriate
techniques due to their plasticity to give rise to terminally
differentiated tissues. Their relative low abundance in source
tissues, however, triggered attempts to expand them in vitro
that raised various technical challenges including the preven-
tion of their premature senescence.
1.1. Cellular Senescence. Cellular senescence, first described in
fibroblast cultures, is a dynamic multistep process resulting in
permanent proliferation arrest in response to various stimuli
[2, 3]. At the molecular level, senescence is mediated by upreg-
ulation of the cyclin-dependent kinase inhibitor p16 and p21
with subsequent p53 stabilization [4]. Growth arrest is, even-
tually, accompanied by phenotypical hallmarks including dys-
regulation of the nuclear morphology, cytoplasmic inclusion
of the chromatin, and the enlarged cytoplasm [5, 6]. The latter
is characterized by enlarged, granular morphology, formation
of actin stress fibers, mitochondrial accumulation, and
lysosomal dysfunction and is, at least in part, mediated by
the constitutive activation of the mTOR pathway [4]. At the
transcriptional level, these phenotypic changes seem to be
accompanied by fundamental alterations in gene expression
patterns leading to upregulation of a number of signaling
pathway that exert antiapoptotic effects [7–9]. In addition,
the modified transcriptional pattern is also biased toward the
robust expression of proinflammatory cytokines, chemokines,
growth factors, and matrix-remodeling proteins culminating
in the so-called senescence-associated secretory phenotype
(SASP) [10]. Recent proteomic analysis of the SASP revealed
that the SASP secretory profiles show high degree of heteroge-
neity among distinct cell types and senescence-inducing stim-
uli drawing an intricate picture of the senescence-specific
transcriptional mechanisms [11]. Indeed, network analysis of
the senescent transcriptome suggests upregulation of proteins
like the hypoxia-inducible factor 1 (HIF1) as well as indicating
the comprehensive nature of the changes of the senescent
intracellular milieu [12]. Premature ex vivo senescence of stem
cells prompted investigations on culturing methods including
the use of differential oxygen tensions, exploiting the idea that
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low oxygen mimics one of the key aspects of the natural niche
where these cells reside and, thus, help maintain critical
phenotypic properties in vitro.
1.2. Mesenchymal Stromal Cells. Stem cells are typically
grouped into two major classes: embryonic and adult stem
cells. The former ones are long-known since cells in the inner
cell mass of the blastocyst give rise to all the adult tissues
ensuring physiologic organogenesis [13]. Adult stem cells
are more tissue-specific and contribute to the remodeling of
dedicated tissues only. They are found in various organs
where their microenvironment critically affects their ability
to differentiate [14]. One of these specialized niches is the
bone marrow where adult stem cells are the most abundant
in the form of hematopoietic and non-hemopoietic species
[15]. The latter ones, termed bone marrow-derived mesen-
chymal stromal cells (BMSCs), were first identified by Frie-
denstein in 1976 [16]. BMSCs are multipotent species with
the potential to differentiate into diverse mature cells in the
mesenchymal lineages including adipo-, chondro-, and oste-
ocytes, fibroblast, or, under certain conditions, other meso-
dermal cell types [17]. Additional characteristic features of
BMSCs are that they are plastic-adherent in culture and
express CD105, CD73, and CD90 surface markers but nega-
tive for CD45, CD34, CD14 or CD11b, CD79alpha, CD19,
and HLA-DR [18]. At least in part due to the latter feature,
BMSCs do not show alloreactivity in lymphocyte prolifera-
tive assays suggesting that they are suitable for transplanta-
tion between non-compatible HLA individuals [19]. Since
human BMSCs (hBMSCs) have been shown to be able to dif-
ferentiate into pericytes, myofibroblasts, osteocytes, and
other mature cells contributing to the formation of the bone
marrow microenvironment, they seem to play a role in regu-
lating hemopoiesis by maintaining the hemopoietic microen-
vironment [20, 21] Indeed, transplantation of hBMSCs into
the murine bone marrow was found to be sufficient to the
reconstitution of the human bone marrow microenviron-
ment and the formation of primitive human hemopoietic
cells in the murine bone marrow [22]. It has also been well
documented that, in humans, co-transplantation of hemo-
poietic precursors and hBMSCs improves hemopoietic
recovery following therapeutic bone marrow transplantation
[23, 24]. Besides their putative structural roles, hBMSCs
maintain and develop the bone marrow microenvironment
and support hemopoietic cells by producing various different
cytokines as well [25]. In accordance, in vivo studies showed
the constitutive expression of interleukin-1 and -6 (IL-1, IL-6,
respectively), macrophage colony-stimulating factor (M-
CSF), and stem cell factor (SCF) by hBMSCs differentiated
towards the osteogenic lineage [26]. This, however, not only
includes physiologic states but also occurs relevant in patho-
logic conditions. Indeed, the inflammatory bone marrow
microenvironment of obese animals promotes mouse BMSC
(mBMSC) differentiation into adipocytes [27]. These data
suggest that hBMSCs are not only important factors in the
maintenance of the bone marrow compartment but that
microenvironmental stimuli might also be critical in their
physiology including their reduced senescence that allows
prolonged lifespan within their natural niche [28, 29]. BMSC
senescence is a critical aspect of their use of cellular therapy
since senescent BMSCs show differential proliferation and
differentiation capacity [30]. Senescence is a particular chal-
lenge in BMSC-based cellular therapy due to the observations
that senescent BMSCs also show reduced dynamics of micro-
filaments accompanied by impaired migration [31]. In addi-
tion, downregulation of numerous cytokine and chemokine
receptors including the chemokine receptor type 4 (CXCR4)
and chemokine receptor 7 (CCR7) is another characteristic
finding in senescent BMSCs that might also contribute to
the impaired migration of these cells, one of the critical
aspects of their therapeutic potential [32]. One of the charac-
teristic features of the bone marrowmicroenvironment is low
oxygenation raising the question if local hypoxia is an essen-
tial microenvironmental factor of bone marrow-residing
cells. Mathematical models predict that hemopoietic stem
cells are localized to poorly vascularized bone marrow
regions suggesting that the hypoxic microenvironment is
essential for their homeostasis [33]. Indeed, consistent results
were found in mice showing that hemopoietic cells reside in
the hypoxic bone marrow niche [34]. Based on these data,
one can speculate that local hypoxia in the bone marrow is
an important microenvironmental factor in the physiology
of BMSCs as well [35].
1.3. Hypoxia.Due to the fundamental role of oxygen in cellu-
lar physiology, oxygen depletion—hypoxia—is most often
associated with pathologic conditions. Hypoxia, however, is
an integral part of the development and maintenance of cer-
tain organs and tissues. Indeed, cytotrophoblasts proliferate
in the 2% oxygen environment, whereas at 20% oxygen, they
stop proliferating and undergo differentiation [36]. In accor-
dance, the reproductive track of mammals is hypoxic, with
O2 levels ranging from 1.5% to 8.7% until significant vascu-
larization and formation of the placenta occurs towards the
end of the first trimester [37, 38]. Thus, it is not surprising
that embryonic stem cells have to be exposed to a hypoxic
environment to maintain their pluripotency suggesting that
oxygen affects intrinsic stem cell properties [39]. Interest-
ingly, during syncytiotrophoblast formation, the expression
of senescence markers was also observed raising the question
of a potential link between the hypoxic adaptation and
molecular machinery of senescence [40]. Hypoxia is charac-
teristic not only of embryogenesis but also the physiology
of adult organs, including the bone marrow raising the ques-
tion if low oxygen tension has similar physiologic role of
bone marrow-residing cells including hBMSCs than that of
the emryonic stem cells. In support of this idea, hBMSCs
were found to show higher proliferation rates in hypoxic
conditions and remain undifferentiated at 2% oxygen levels
indicating that hypoxia has complex effects on BMSCs [41].
1.4. Intracellular Response to Hypoxia. Cells in the low oxygen
environment have intracellular signaling mechanisms that
allow adaptation and response to reduced oxygen availability.
The hypoxia-triggered complex molecular events are primar-
ily orchestrated by the HIFs first identified as nuclear factors
interacting with the 3′ enhancer sequence of the erythropoie-
tin (EPO) gene in response to hypoxia [42]. It is made of two
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subunits: HIF-alpha (HIFα) and -beta (HIFβ) of which the
former one is responsive to oxygen levels while the latter is
constitutively expressed [43]. In the presence of oxygen, HIFα
is hydroxylated on conserved proline residues by prolyl
hydroxylases (PHDs) [44]. This causes a conformation change
in HIFα exposing a binding site for the von Hippel-Lindau
(pVHL) ubiquitin ligase that polyubiquitylates hydroxylated
HIFα for degradation [44, 45]. Since PHDs use molecular oxy-
gen for the hydroxylation, they are considered to be the pri-
mary sensors of intracellular oxygen levels [46]. Indeed, in
hypoxic conditions, hydroxylation and consequent degrada-
tion of HIFα fail leading to stabilization and dimerization of
HIFα with the β subunit to upregulate the expression of mul-
tiple hypoxia-adaptive genes [47]. These include, for instance,
the vascular endothelial growth factor (VEGF) that contributes
to the survival of cells exposed to hypoxic conditions by facil-
itating angiogenesis [48]. The HIF-VEGF axis is functional in
hypoxia-exposed hBMSCs suggesting that the unfold of their
hypoxic phenotype is, at least in part, orchestrated by the
HIF-mediated machinery [47].
1.5. Molecular Characteristics of BMSCs in the Oxygen-
Depleted Environments. In cells exerting oxygen-dependent
adenosine triphosphate (ATP) production, most of the oxy-
gen is consumed by the oxidative phosphorylation. hBMSCs
grown at 20% oxygen show a 2-fold increase in oxygen con-
sumption in mitochondria compared to cells kept in hypoxic
conditions that, in return, need to adjust their metabolism to
adapt to oxygen depletion [49]. hBMSCs cultured at low oxy-
gen tensions display elevated glucose uptake besides reduced
incorporation of glucose-derived carbons in tricarboxylic
acid cycle (TCA) intermediates indicating a complex meta-
bolic switch in order to maximize energy production under
anaerobic conditions (Figure 1.) [50]. In addition, hypoxic
hBMSCs also display differential utilization of the carbon
source glutamate in the TCA cycle. The accompanying low
ammonia production, however, suggests that glutamate is
primarily metabolized by transaminases rather than gluta-
mate dehydrogenases in hypoxic hBMSCs [50]. Transamina-
tion does not lead to ammonia production upon the
glutamate metabolism, and this may be beneficial to cells as
ammonia is considered to be toxic to hBMSC cultures [51,
52]. Thus, the observation that hBMSCs grown at 2% oxygen
show higher proliferation rates compared to hBMSCs kept at
20% oxygen raises the question if the differential proliferative
capacity is, at least in part, due to the reduced ammonia pro-
duction under hypoxic in vitro conditions [53]. Since prolif-
eration often inhibits differentiation, one can speculate if
hypoxia interferes with the differentiation capacity of BMSCs
[54]. Indeed, the expression of telomerase reverse transcrip-
tase (TERT) and octamer-binding protein 4 (OCT4), markers
of undifferentiated cells, increases in hypoxic hBMSCs [55]
(Figure 1). In addition, hypoxia seems to increase the sub-
population of G1-arrested hBMSCs cells that, apparently, fail
to differentiate into bony or adipose tissues [56]. In contrast,
however, other studies found elevated proliferation in both
human and rodent hypoxic BMSC cultures accompanied by
the repressed OCT4 expression which may reflect the
presence of distinct subpopulations in BMSC cultures that
respond differentially to hypoxia [57, 58]. Indeed, cells that
are more engaged toward the osteoblast lineage seem to
behave differently than those more biased toward chondro-
or adipogenesis. This concept is supported by findings that
hypoxic hBMSC fail to display osteogenic characteristics
such as calcification or alkaline phosphatase after 14 and 21
days of culture [49]. In accordanec, RUNX family transcrip-
tion factor 2 (RUNX2), osteocalcin (BGLAP), and type I col-
lagen (COLI) are all repressed in hypoxic hBMSCs while
VEGF is induced suggesting that the HIF pathway is activated
in these cells while the osteogenic machinery is not fully
engaged [59] (Figure 1). These observations suggest that,
for differentiation into osteogenic lineage, BMSCs need to
be cultured at normoxic conditions. Interestingly, when hyp-
oxic hBMSCs are transferred to normoxic conditions, cul-
tures show osteogenic heterogeneity with differential
osteogenic potential and suggesting that hypoxic adaptation
induces permanent molecular changes that interfere with
the, apparently, oxygen-demanding osteogenic programme
[49]. In contrast, hypoxic hBMSCs show augmented adipo-
genic potential with induced adipocyte-specific genes and
accumulation of lipid droplets compared to cells kept under
normoxic culture conditions after 7-20 days [58, 60]. It is
noteworthy, however, that there are also reports on attenu-
ated adipogenesis under differential hypoxic conditions.
Long-term hypoxia, for instance, apparently blocks adipo-
genic differentiation in hBMSC [61]. Although the exact rea-
son of the higher oxygen demand of osteogenesis is not clear,
it may be related to the decreased oxidative phosphorylation
capacity of hypoxic BMSCs [49]. Alternatively, considering
terminal differentiation as a special form of senescence, one
can speculate if hypoxia interferes with the osteogenic differ-
entiation of BMSCs by blocking their lineage-specific
senescence.
1.6. BMSC Senescence and Low-Oxygen Conditions. There is a
growing body of evidence that hypoxia affects BMSC senes-
cence, at least in part by reprogramming cellular carbohy-
drate metabolism [49] (Table 1). Indeed, metabolites, like
glyoxal, triggers hBMSC senescence which is accompanied
by elevated levels of metabolic senescence markers including
the senescence-associated β-galactosidase (SA-β-Gal) or α-
L-fucosidase (α-Fuc) activity [62]. Moreover, metabolomics
of the bone marrow of patients suffering from cyanotic
congenital heart disease (CCHD) revealed enormously
increasedD-galactose levels provoking premature senescence
of patient’s BMSCs [63]. D-Galactose is a well-known
senescence-inducing metabolite that acts, primarily, via oxi-
dative stress [64]. Interestingly, elevated SA-β-Gal levels are
long-recognized markers of senescence, so one can speculate
that the role of D-galactose in BMSC senescence may not be
necessarily restricted to severe chronic hypoxic conditions.
Indeed, hBMSCs isolated from older, but not hypoxic donors
also show elevated SA-β-Gal and lipofuscin levels parallel
with reduced proliferative capacity compared to hBMSCs
obtained from younger donors [65, 66]. Based on these
findings, it seems that hypoxia has a pro=senescence effect
in humans via senescence provoking metabolic changes
(Figure 1).
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The complex adaptive measures activated in oxygen-
depleted environments, apparently, affect lipid metabolism
as well. Indeed, the fatty acid binding protein 3 (FABP3),
the muscle and heart-specific member of the fatty acid bind-
ing protein family, is upregulated in hypoxic hBMSCs [67].
FABP family members not only regulate the lipid metabolism
and phospholipid biosynthesis, critical aspects of energy
production and cell division, respectively, but also facilitate
proliferation of endothelial cells and contribute to adipogenic
differentiation as well [68–70]. Interestingly, however,
hypoxia-induced FABP3 inhibits proliferation of hBMSCs
that, in return, may reduce the accumulation of replicative
mutations and, thus, senescence [67]. Indeed, in vitro









































Figure 1: Schematic overview of the effects of hypoxia on BMSC senescence. Oxygen depletion induces or activates a number of cellular
processes that delay or reverse cellular senescence in BMSCs. These include induction of stem cell-specific genes, upregulation of the HIF
pathway and its effectors, or activation of autophagy. Parallel, hypoxia represses prosenescence factors like production of reactive oxygen
species or expression of genes involved in cell cycle arrest and reduce activity of signaling cascades like the mTOR pathway. Abbreviations
used are OCT4: octamer-binding protein 4; FABP3: fatty acid binding protein 3; TWIST: basic helix-loop-helix transcription factor; HIF1:
hypoxia-inducible factor 1; IHH: Indian Hedgehog protein; MIF: macrophage inhibitory factor; SATB2: special AT-rich binding protein 2;
mTOR: mammalian target of rapamycin; ROS: reactive oxygen species.
Table 1: Summary of studies investigating the effects of hypoxia on BMSC senescence.
Study findings References
Proliferation and cellular metabolism of hypoxic human BMSCs [47, 50, 53, 56, 58, 63, 67, 82–84]
Proliferation and osteogenic capacity of hypoxic rat BMSCs [103]
Osteogenic differentiation of hypoxic human BMSCs [49, 55, 56, 58, 61, 63, 82, 104, 106, 107]
Adipogenic differentiation of hypoxic human BMSCs [56, 58, 60, 61, 63, 82, 107]
Chondrogenic capacity of hypoxic human BMSCs [63, 82, 107]
Chondrogenic capacity of hypoxic rat BMSCs [57]
Autophagy in hypoxic human BMSCs [94]
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mutations and chromosomal instabilities that eventually lead
to cell cycle arrest and senescence [71]. Senescent BMSCs
also accumulate reactive oxygen species (ROS) that, via oxi-
dative DNA damage, not only reduce differentiation capacity
but also upregulate p53 and p21, markers of senescence, lead-
ing to cell cycle arrest [72–76]. Senescent hBMSCs show ele-
vated p53 and p21 activity and genetic ablation of p21 reverse
senescent phenotype [77–79]. In addition, antioxidants or
reduced ROS production slow premature senescence of
hBMSCs and repress p21 and p53 expression [80, 81]. Thus,
despite findings of the metabolic adaptation-triggered senes-
cence, one can speculate that hypoxic conditions lead to an
overall decrease of senescence by reducing ROS formation.
Indeed, culturing BMSCs under the hypoxic condition has
been reported to inhibit senescence and promote the undif-
ferentiated status of cells [82, 83]. These phenotypic effects
are preceded by HIF-mediated induction of the basic helix-
loop-helix transcription factor TWIST (TWIST1) that results
in consequent downregulation of p21 in hBMSCs [84]. In
addition, in rodent cells, the antisenescence effect of HIF is,
apparently, mediated by the HIF upregulated macrophage
inhibitory factor (MIF), a known downregulator of p53
supporting the idea that the overall effect of hypoxia is rather
anti-senescent and is mediated by the HIF pathway via
multiple effectors [85] (Figure 1).
Similarly, contradicting results were obtained in studies
analyzing the telomere length, another hallmark of senes-
cence, of BMSCs under hypoxia. Cells with telomeres shorter
than 10 kb usually show senescent phenotype including p53
and p21 activation and telomere aggregation that also leads
to further DNA damage, and these hallmarks have been
reported in senescent hBMSCs as well [86–88]. However,
whether these changes are prevented or reverted by keeping
BMSCs in the low oxygen environment is not clear as both
elevated telomerase activities accompanied by increasing
telomere length and telomere shortening have been observed
in hypoxic hBMSC cultures [53, 84]. For the former one, the
NAD-dependent protein deacetylase Sirtuin 1 (SIRT1) was
reported to be involved in the maintenance of the telomerase
activity and reduction of DNA damages at chromosomal
ends in rat BMSCs (rBMSC). Indeed, inhibition of SIRT1 in
young rBMSCs leads to premature senescence while its
upregulation in old rBMSCs, apparently, decreases senescent
phenotype and increases proliferation [89]. If SIRT1, how-
ever, is involved in the maintenance of telomeres under hyp-
oxic conditions that is yet to be elucidated since, under
hypoxia, intracellular NADH levels increase resulting in
repression of SIRT1 in established cell lines [90]. In addition,
SIRT1 deacetylates HIF-1 and, thus, attenuates its transacti-
vation activity, thereby counteracting HIF-mediated effects
in hypoxic tubulointerstitial kidney cells [91]. Thus, the
possible role of SIRT1 in the regulation of telomere length
in hypoxic hBMSCs needs further investigations.
Besides the abovementioned metabolism-related mecha-
nisms, autophagy also seems to be important in the mainte-
nance of stem cell phenotype and inhibition of senescence
[92]. Indeed, inhibition of autophagy by the autophagy
inhibitor 3-methyladenine leads to early senescence of
mBMSC. In contrast, activation of autophagy increases the
proliferative capacity of the same cells [93]. Hypoxia, appar-
ently, upregulates autophagy in hBMSCs by repression of the
mTOR pathway, a known inhibitor of autophagy [94, 95].
Indeed, suppression of the mTOR pathway and ROS produc-
tion by the Indian Hedgehog (IHH) protein reverses the
senescent phenotype in hBMSCs including the downregula-
tion of its own receptors PTCH1/2, one of the molecular
hallmarks of aging hBMSCs [96, 97] (Figure 1). Another
potentially autophagy-related regulator of BMSC senescence
is the special AT-rich binding protein 2 (SATB2) that seems
to be responsible for the elevated autophagy activity accom-
panied by higher pluripotency and anti-senescence capacity
of mandibular hBMSC under both normoxic and hypoxic
conditions. Activation of SATB2 leads to the increased
expression of autophagy-related genes via the mTOR signal-
ing pathway [98]. Furthermore, exogenous expression of
SATB2 in tibial hBMSC leads to increased autophagic
capacity and pluripotency [98].
2. Discussion
Since their low frequency in adult tissues requires in vitro
expansion for cellular therapy purposes, understanding the
mechanisms underlying BMSC senescence seems to be criti-
cal to the development of efficient BMSC-based therapeutical
modalities. Still, our current knowledge on the effects of
BMSC senescence is often controversial. Indeed, while secre-
tion of proinflammatory agents by non-stem senescent cells
favors M1 macrophage differentiation, senescent hBMSCs
seem to retain anti-inflammatory properties by inhibiting
both macrophages and lymphocyte proliferation [99–101].
Although this may suggest that BMSC senescence is not nec-
essarily disadvantageous from the therapeutical point of
view, it is now widely accepted that BMSC senescence funda-
mentally alters cellular characteristics so that it unfavorably
affects their clinical potential.
Current data suggest that, during senescence, one of the
affected aspects of cellular homeostasis is the carbohydrate
metabolism. Data also suggest that, during oxygen depletion,
the altered carbohydrate metabolism might contribute to the
anti-senescence effect of hypoxia. Some data, however, sug-
gest that certain aspects of the hypoxia-triggered metabolic
alterations, like the increased D-galactose load, might also
facilitate pro-senescence processes. Thus, these observations
raise the question if the composition of the carbohydrate
supply is critical in determining the overall effect of hypoxic
preconditioning during ex vivo culturing of hBMSC.
Apparently, reactive oxygen species also play pivotal role
in BMSC senescence so measures that reduce ROS produc-
tion may also be considered effective in vitro interventions
to prevent BMSC senescence. Indeed, reduction of the oxy-
gen load by exposing cells to hypoxic environmental condi-
tions seems to prolong BMSC lifespan and preserve their
differentiation capacity toward, at least, the chondro- and
adipogenic lineages. By the most plausible explanation,
hypoxia reduces ROS formation that, consequently, leads to
less molecular damage to cellular components. This idea is,
apparently, supported by observations that mechanisms that
are involved in the elimination of damaged cellular
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components, like autophagy, can revert the senescent pheno-
type. In accordance, besides lysosome-mediated autophagy,
the proteasome system also seems to be involved in the con-
trol of BMSC senescence. Indeed, downregulation of ubiqui-
tin C (UBC) leads to replicative senescence in BMSC the
overexpression of UBC in hBMSC leads to increased prolifer-
ation and repression of senescence [102]. Unfortunately, no
significant data was obtained on UBC expression under
different oxygen conditions to date so determination of the
potential role of ubiquitination in BMSCs senescence under
hypoxia needs further investigation.
Although the use of the low oxygen environment for
ex vivo culturing of BMSCs seems logical, conflicting obser-
vations on the behavior of BMSC cultures under in vitro hyp-
oxic conditions indicate the need of further investigation to
detail the optimal use of hypoxia for BMSC expansion. These
investigations, however, need to be standardized since cur-
rent data indicate species-specific BMSC responses to hyp-
oxia. Indeed, while rBMSCs show increased proliferation
and expression of osteogenic lineage markers, like the alka-
line phosphatase activity and accumulation of calcium under
hypoxic culture conditions, hBMSCs show paralyzed osteo-
genic differentiation in oxygen-depleted cultures [103, 104].
Similarly, senescence achieved by hBMSCs due to shortened
telomeres is irreversible while rat BMSCs can escape the
telomere shortening-mediated senescence and become
malignant [105].
The mode of application of hypoxia to ex vivo expanded
BMSCs needs further characterization as well. Short-term
hypoxia seems to be beneficial in terms of BMSC senescence
while long-term pathological hypoxia induces premature
senescence in human BMSCs. Indeed, BMSCs from patients
with CCHD were predisposed to premature senescence and
had impaired multi-lineage differentiation potential [63].
Beside duration, the mode of exposure also seems to be crit-
ical. Hypoxic pre-conditioning of rBMSCs for 7 days
followed by 7 day-long exposure to ambient oxygen condi-
tions results in increased proliferation, augmented osteogenic
differentiation, and induction of the anti-apoptotic B-cell
CLL/lymphoma 2 (BCL2) and Bcl-2-like protein 1 encoding
genes (BCL2L1) compared to cultures kept under either
ambient air or hypoxia continuously for 14 days [106].
Some data, however, suggest that even hypoxia is not
capable to reverse all aspects of senescence. BMSCs isolated
from elderly patients suffering from osteoarthritis failed to
show robust differentiation into osteo-, chondro-, or adipo-
cyte lineages under hypoxic conditions. These BMSCs dis-
play reduced expression of cell lineage-specific genes like
the SRY-box transcription factor 9 (SOX9) and collagen type
I alpha 1 chain (COL1A1) for chondrocyte lineage, alkaline
phosphatase (ALPL), and osteogenic protein (OP) for osteo-
cyte lineage and BGLAP and fatty acid binding protein 4
(FABP4) for adipocyte lineage compared to cells from the
same isolates kept under ambient oxygen tensions indicating
the potential pro-senescence effect of the chronic inflamma-
tory milieu and/or exhausted adaptive measures to cope with
hypoxia [107]. In addition, premature senescence of BMSCs
of CCHD patients seems to be mediated by gut microbiota
dysbiosis, especially by reduction in Lactobacillus, via sys-
temic deviation in carbohydrate metabolism indicating that
even, apparently, irrelevant underlying medical conditions
may affect the quality of isolated BMSCs [63].
3. Conclusion
Despite the occasionally conflicting observations on the
effects of oxygen depletion on BMSC senescence, hypoxic
exposure of human BMSCs is now believed to be beneficial
for delaying permanent cell cycle arrest of ex vivo cultured
BMSCs. However, further investigations are needed to define
detailed protocols that minimize the potentially disadvanta-
geous effects of hypoxic preconditioning while maximizing
its anti-senescent ones. These works, at the same time, will
not only help to understand the role of oxygen in cellular
senescence but shed light on the underlying molecular mech-
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